← All trials
NCT07012837
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 31, 2025
- Primary completion
- Jul 31, 2027
- Completion date
- Aug 31, 2027
- First posted
- Jun 10, 2025
- Last posted
- Jun 10, 2025
- Enrollment
- 112
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Imam Abdulrahman Bin Faisal UniversityLead sponsor
- Imam Abdulrahman Bin Faisal UniversityOfficial
- Imam Abdulrahman Bin Faisal UniversitySponsor investigator
Drugs studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.